Entera's present strategy is to develop drugs that can go into the marketplace as quickly as possible.

Teriparatide (PTH 1-34) is the active component of the parathyroid hormone. PTH 1-34 is a known active pharmaceutical ingredient commercially available as an injection for over a decade. PTH 1-34 has been selected as Entera’s lead candidate for its first oral drug.

Entera develops drugs based on PTH 1-34 for three separate therapeutic applications: hypoparathyroidism, osteoporosis, and bone healing. There are minor differences between the drugs, mostly modifications of the formulation and dosing regimen. The active component of these drugs has proven its efficacy in non-oral drugs for all three applications.

Entera plans to complete Phase 2 clinical trials for the drugs and collaborate with strategic partners in Phase 3 trials.